Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Form 144 notice of proposed sales of Common Stock tied to option exercises and recent open‑market dispositions. The filing lists multiple option‑exercise issuances dated 07/01/2021, 07/03/2023, 07/02/2018, 07/01/2020, and 07/01/2019 for 12,000; 10,321; 16,000; 12,000; and 16,000 shares respectively. It also reports that Joseph Loscalzo sold 832 shares on 03/03/2026 for $66,833 and 200 shares on 03/04/2026 for $16,000.
Ionis Pharmaceuticals executive Joseph Baroldi reported an open-market sale of company stock. On this Form 4, the EVP and Chief Business Officer sold 1,626 shares of Ionis Pharmaceuticals common stock on April 28, 2026 at a weighted average price of $71.7877 per share in an open-market transaction.
The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted by Baroldi on November 25, 2025. After the transaction, he directly owned 44,909 shares of common stock. A separate holding entry shows 4,347 shares of common stock held indirectly by his spouse.
Vanguard Capital Management reported beneficial ownership of 8,344,732 shares of Ionis Pharmaceuticals common stock, representing 5.05% of the class. The filing lists sole voting power over 1,226,402 shares and sole dispositive power over 8,344,732 shares. The Schedule 13G is signed by Vanguard's Head of Global Fund Administration.
Ionis Pharmaceuticals reported strong growth for the quarter ended March 31, 2026, with total revenue of $246.1 million, up from $131.6 million a year earlier, driven by new product launches and collaboration milestones. Product sales rose to $43.0 million, led by TRYNGOLZA and DAWNZERA, while royalty revenue was $58.3 million. Research and development revenue more than doubled to $138.3 million, helped by a $50 million milestone from Roche and $30 million of milestones from GSK. The company’s net loss narrowed to $92.5 million, compared with $146.9 million in the prior-year quarter, as higher revenue offset increased commercial and R&D spending. Ionis ended the quarter with $173.4 million in cash and cash equivalents and $1.75 billion in short-term investments, supporting ongoing launches and late-stage development, despite a large operating cash outflow related to funding the upcoming maturity of its 0% convertible notes due 2026.
Ionis Pharmaceuticals reported strong first quarter 2026 results and raised its full-year outlook. Total revenue rose to $246 million from $132 million a year earlier, driven by higher product sales of TRYNGOLZA and DAWNZERA and increased research and development revenue, including about $95 million of partnership milestones.
Despite the growth, Ionis recorded a GAAP net loss of $93 million, improving from a $147 million loss last year. Cash, cash equivalents and short-term investments were $1.9 billion as of March 31, 2026, with an additional $633 million held in escrow for 0% convertible notes maturing in April 2026.
Reflecting its momentum, Ionis increased 2026 total revenue guidance to $875–900 million and introduced product sales targets of $100–110 million for TRYNGOLZA and $110–120 million for DAWNZERA. The company also narrowed its expected 2026 non-GAAP operating loss to $425–475 million and reaffirmed a year-end liquidity goal of more than $1.6 billion.
IONS: A Rule 144 notice reports planned and recent sales of Common Stock. The record lists 10,837 restricted shares tied to an 04/15/2022 award with a 04/15/2026 date and three reported open-market sales by Joseph Baroldi on 01/30/2026, 03/03/2026, and 04/16/2026.
Ionis Pharmaceuticals, Inc. is asking stockholders to vote at its 2026 virtual Annual Meeting on June 4, 2026. Stockholders of record as of April 7, 2026 may attend online, submit questions and vote using a 16-digit control number.
The agenda includes electing two directors, an advisory “say on pay” vote on executive compensation, and ratifying Ernst & Young LLP as independent auditors for fiscal 2026. Ionis also seeks approval to amend its 2011 Equity Incentive Plan to add 9,500,000 shares, bringing the plan total to 52,000,000 shares, and to amend its 2000 Employee Stock Purchase Plan to add 750,000 shares and remove the plan’s termination date.
The proxy materials describe the company’s classified board structure, committee responsibilities, risk oversight, executive team, corporate governance practices, and compensation philosophy, including increased use of performance-based restricted stock units, stock ownership guidelines, a clawback policy, and prohibitions on hedging and pledging company stock.
Ionis Pharmaceuticals reported additional positive results from its pivotal Phase 1-3 study of zilganersen in Alexander disease, a rare and often fatal neurological disorder with no approved disease‑modifying treatments. In patients aged ≥5, zilganersen 50 mg met the study’s primary endpoint by stabilizing gait speed on the 10‑Meter Walk Test at Week 61 versus control, showing a 33.3% least‑square mean difference (p=0.041). In children aged 2‑4, Gross Motor Function Measure‑88 results suggested improved gross motor function versus control. Multiple patient, caregiver and clinician‑reported secondary endpoints generally favored zilganersen, and an exploratory analysis showed a 33.6% reduction in plasma GFAP levels at Week 61 versus control. Safety was described as favorable, with serious treatment‑emergent adverse events less frequent than in the control group. Zilganersen is under FDA Priority Review with a Prescription Drug User Fee Act action date of September 22, 2026.
IONIS PHARMACEUTICALS INC director Lynne B. Parshall reported selling 5,000 shares of common stock in open-market transactions. The sales occurred on April 15, 2026 in two tranches: 4,466 shares at a weighted average price of $76.19 and 534 shares at a weighted average price of $76.97.
These trades were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on May 6, 2025, indicating they were scheduled in advance. Following the transactions, Parshall directly holds 51,344 shares of Ionis common stock.